In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients.

Vivek TiwariTomoyuki MashimoZhongxu AnVamsidhara VemireddySara PiccirilloPegah AskariKeith M HulseyShanrong ZhangRobin A de GraafToral R PatelEdward PanBruce E MickeyElizabeth A MaherRobert M BachooChangho Choi

Published in: Magnetic resonance in medicine (2020)

The similarity of 2HG production between PDX models and parental-tumor patients indicates that PDX tumors retain the parental IDH metabolic fingerprint and can serve as a preclinical model for improving our understanding of the IDH-mutation associated metabolic reprogramming.

Keyphrases

end stage renal disease
chronic kidney disease
newly diagnosed
ejection fraction
peritoneal dialysis
prognostic factors
patient reported outcomes
bone marrow
mesenchymal stem cells
patient reported